Applied Research
Berkeley is one of Bayer HealthCare Pharmaceutical's three Research & Development centers of excellence... more
We at Bayer are committed to producing and enhancing therapies that treat complex medical conditions—therapies which meet high standards of quality, safety and efficacy.
Read more about our work in hemophilia, multiple sclerosis and acute myelogenous leukemia.
* Kogenate® FS Antihemophilic Factor (Recombinant), is a recombinant Factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. For important safety and use information, please see the full prescribing information.
* Product information is intended for U.S. Audiences Only
